Headquartered in San Francisco, CA Fiscal year ends December NASDAQ: HTFL heartflow.com
Heartflow, Inc. is a medical technology company that uses artificial intelligence to diagnose and manage coronary artery disease (CAD). The company's Heartflow One platform transforms coronary CT angiography (CTA) images into personalized 3D models of the heart, providing clinically meaningful insights into plaque location, volume, composition, and blood flow effects without invasive procedures. Heartflow offers two primary products: Heartflow FFRCT Analysis, which assesses the functional significance of coronary blockages, and Heartflow Plaque Analysis, an emerging growth product that characterizes coronary plaque. The company's technology has been adopted by more than 1,800 institutions globally and is backed by ACC/AHA guidelines and over 625 peer-reviewed publications. Heartflow has analyzed care for more than 750,000 patients worldwide and its AI models are built from the world's largest database of more than 200 million annotated CTA images. The company generates revenue primarily in the United States with a smaller international presence, and operates on a per-case revenue model. Updated
After a week of wild swings that rattled portfolios and left investors guessing, Wall Street analysts are already reshuffling their ratings on Friday morning, with some surprising cuts and upgrades across sectors…
Heartflow, Inc. is a medical technology company that uses artificial intelligence to diagnose and manage coronary artery disease (CAD).
The Wall Street consensus 12-month price target for HTFL is $47.22.
